Overview

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with more than one chemotherapy drug (combination chemotherapy), may be a better way to block tumor growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Aromatase Inhibitors
Bevacizumab
Cyclophosphamide
Doxorubicin
Immunoglobulins
Lenograstim
Liposomal doxorubicin
Paclitaxel
Tamoxifen